Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21314975 | 0.85 | MEN1 (0.40) | MEN1KMT2AGRM2SCDMAPK1 | |
| SCHEMBL7425205 | 0.80 | SMYD3 (0.50) | MEN1KMT2AGRM2MAPK1ADAMTS5 | |
| SCHEMBL16563562 | 0.79 | CNR2 (0.39) | CNR2KDM2BPHF8SCDSMYD3 | |
| SCHEMBL14225445 | 0.79 | MEN1 (0.44) | MEN1KMT2AGRM2MAPK1ADAMTS5 | |
| SCHEMBL4891287 | 0.79 | MEN1 (0.44) | MEN1KMT2AGRM2MAPK1ADAMTS5 | |
| SCHEMBL16535011 | 0.78 | MEN1 (0.42) | MEN1KMT2AGRM2MAPK1ADAMTS5 | |
| SCHEMBL2282033 | 0.78 | CPB2 (0.45) | MEN1KMT2AGRM2MAPK1ADAMTS5 | |
| SCHEMBL21361934 | 0.76 | MEN1 (0.43) | MEN1KMT2AGRM2MAPK1ADAMTS5 | |
| SCHEMBL15775548 | 0.76 | MEN1 (0.43) | MEN1KMT2AGRM2MAPK1ADAMTS5 | |
| SCHEMBL29016719 | 0.76 | MEN1 (0.40) | MEN1KMT2AGRM2MAPK1ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709374-A2 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024233885-A2 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN2, HCN1, HCN4 | MEN1 1471/4885KMT2A 2862/4885GRM2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.